ProCE Banner Activity

Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

Podcast Episodes
In this podcast episode, listen to Prof Isabelle Ray-Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on trials of interest including novel HRD testing for ovarian cancer, OS results from ARIEL3, and QoL outcomes for rare nonepithelial ovarian cancers following chemotherapy.

Released: November 30, 2022

Expiration: November 29, 2023

Share

Faculty

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Prof Isabelle Ray-Coquard, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, GlaxoSmithKline, MSD.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD: consultant/advisor/speaker: Agenus, Akesobio, AstraZeneca, Bristol-Myers Squibb, Deciphera Pharmaceuticals, Eisai, Elevar Therapeutics, Exelixis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, Immunogen, Jazz, Karyopharm, Mersana, MSD, Novocure, Novartis, Oncoinvent, OncXerna, Regeneron, Sanofi, Seagen, Sotio, Verastem Oncology, Zentalis; researcher: Amgen, Roche, Oncoinvent AS.